Zai Lab Limited (NASDAQ: ZLAB) said it will delay regulatory filing for bemarituzumab after final analysis of a Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE